Assignee

NEUPHARMA INC

US·34 granted patents·12 pending applications·164 citations·filing 2012–2023

Technology mixA61P44 A61K39 C07D34 C12Q13 G01N13 C07J9

Top patents by PatentIndex Score

46 records

0198US11304957B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2020·Granted Apr 19, 2022·4 cites·6 claims
0297US11865120B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2022·Granted Jan 9, 2024·2 cites·14 claims
0397US10172868B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2017·Granted Jan 8, 2019·10 cites·25 claims
0497US9849139B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2016·Granted Dec 26, 2017·12 cites·40 claims
0597US9550770B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2014·Granted Jan 24, 2017·15 cites·28 claims
0695US10653701B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2018·Granted May 19, 2020·7 cites·22 claims
0795US9572808B2Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancerNEUPHARMA INC·Filed 2015·Granted Feb 21, 2017·13 cites·11 claims
0895US9249111B2Substituted quinoxalines as B-RAF kinase inhibitorsNEUPHARMA INC·Filed 2012·Granted Feb 2, 2016·13 cites·35 claims
0993US9249110B2Substituted quinoxalines as B-raf kinase inhibitorsNEUPHARMA INC·Filed 2012·Granted Feb 2, 2016·13 cites·40 claims
1092US10947201B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2016·Granted Mar 16, 2021·6 cites·15 claims
1190US12403145B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2023·Granted Sep 2, 2025·0 cites·20 claims
1290US10544106B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2017·Granted Jan 28, 2020·7 cites·27 claims
1390US10065986B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2016·Granted Sep 4, 2018·6 cites·14 claims
1489US9688635B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2013·Granted Jun 27, 2017·10 cites·23 claims
1589US9676813B2Certain steroids and methods for using the same in the treatment of cancerNEUPHARMA INC·Filed 2013·Granted Jun 13, 2017·9 cites·20 claims
1688US9670180B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2013·Granted Jun 6, 2017·9 cites·53 claims
1787US11208388B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2019·Granted Dec 28, 2021·2 cites·17 claims
1886US10065932B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2017·Granted Sep 4, 2018·3 cites·22 claims
1986US9908866B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2017·Granted Mar 6, 2018·5 cites·23 claims
2086US9822081B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2016·Granted Nov 21, 2017·3 cites·20 claims
2184US9725421B2Substituted quinoxalines as B-raf kinase inhibitorsNEUPHARMA INC·Filed 2013·Granted Aug 8, 2017·6 cites·24 claims
2282US10137125B2Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancerNEUPHARMA INC·Filed 2017·Granted Nov 27, 2018·2 cites·26 claims
2382US10047059B2Substituted quinoxalines for inhibiting kinase activityNEUPHARMA INC·Filed 2017·Granted Aug 14, 2018·3 cites·20 claims
2481US10344048B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2016·Granted Jul 9, 2019·2 cites·38 claims
2579US10561652B2Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancerNEUPHARMA INC·Filed 2019·Granted Feb 18, 2020·1 cites·20 claims
2679US2022251049A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2021·Application pending·0 cites
2778US11325940B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2019·Granted May 10, 2022·0 cites·20 claims
2878US2021113593A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2020·Application pending·0 cites
2976US10766920B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2019·Granted Sep 8, 2020·0 cites·29 claims
3076US2024115585A1Methods of treating cancerNEUPHARMA INC·Filed 2023·Application pending·0 cites
3175US2020390763A1Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancerNEUPHARMA INC·Filed 2020·Application pending·0 cites
3274US10457641B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2017·Granted Oct 29, 2019·1 cites·22 claims
3373US12018002B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2021·Granted Jun 25, 2024·0 cites·15 claims
3472US2021040048A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2020·Application pending·0 cites
3571US10759766B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2019·Granted Sep 1, 2020·0 cites·20 claims
3667US2020354398A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2020·Application pending·0 cites
3766US11465975B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2019·Granted Oct 11, 2022·0 cites·30 claims
3865US2024092825A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2023·Application pending·0 cites
3963US2020330486A1Methods of treating cancerNEUPHARMA INC·Filed 2018·Application pending·0 cites
4063US2021163423A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2021·Application pending·0 cites
4162US10487108B2Certain steroids and methods for using the same in the treatment of cancerNEUPHARMA INC·Filed 2017·Granted Nov 26, 2019·0 cites·42 claims
4260US2024207256A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2022·Application pending·0 cites
4359US2024116880A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2021·Application pending·0 cites
4456US10590106B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2018·Granted Mar 17, 2020·0 cites·21 claims
4556US9707202B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2016·Granted Jul 18, 2017·0 cites·18 claims
4655US2017050938A1Substituted quinoxalines as b-raf kinase inhibitorsNEUPHARMA INC·Filed 2016·Application pending·0 cites

Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →